香港股市 已收市

MRK Jan 2025 155.000 call

OPR - OPR 延遲價格。貨幣為 USD。
加入追蹤清單
2.50000.0000 (0.00%)
市場開市。 截至 03:54PM EDT。
全螢幕
前收市價2.5000
開市2.2500
買盤0.0000
賣出價0.0000
拍板155.00
到期日2025-01-17
今日波幅2.2500 - 2.8000
合同範圍
成交量16
未平倉合約
  • Reuters

    US STOCKS-Stocks close with gains, led by Dow as investors look for rate insight

    U.S. stocks were higher on Wednesday, with the Dow leading gains and the S&P 500 setting a closing record, paced drugmaker Merck, while investors looked towards the next piece of inflation data and Federal Reserve commentary for signals on the rate path. Merck & Co advanced 4.96% as the best performer on the Dow after the U.S. Food and Drug Administration approved its therapy for adults suffering from a rare lung condition.

  • Reuters

    US STOCKS-Stocks gain, led by Dow as investors look for rate insight

    U.S. stocks were higher, with the Dow leading gains on Wednesday, and the S&P 500 setting a closing record, paced by gains in drugmaker Merck, while investors looked towards the next piece of inflation data and Federal Reserve policymaker commentary for signals on the rate path. Merck & Co advanced as the best performer on the Dow after the U.S. Food and Drug Administration approved its therapy for adults suffering from a rare lung condition. The blue-chip Dow sits roughly 1% away from breaking the 40,000 level for the first time.

  • Reuters

    US STOCKS-Dow leads gains on Wall Street as investors await rate clues

    The Dow was the best performing of the three major indexes on Wednesday, paced by gains in drugmaker Merck, while as investors looked towards the next piece of inflation data and Federal Reserve policymaker commentary for insight on the rate path. Merck & Co advanced 4.77% as the biggest boost and percentage gained on the Dow after the U.S. Food and Drug Administration approved its therapy for adults suffering from a rare lung condition.